CBLB613: A TLR 2/6 agonist, natural lipopeptide of mycoplasma arginini, as a novel radiation countermeasure

Radiation Research

Volumn 177, Issue 5, 2012, Pages 628-642

  Singh, Vijay K ^a,b   Ducey, Elizabeth J ^a   Fatanmi, Oluseyi O ^a   Singh, Pankaj K ^a   Brown, Darren S ^a   Purmal, Andrei ^c   Shakhova, Vera V ^c   Gudkov, Andrei V ^c,d   Feinstein, Elena ^c   Shakhov, Alexander ^c  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^c CLEVELAND BIOLABS INC   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBLB 613; COBALT 60; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; KERATINOCYTE DERIVED CHEMOKINE; RADIOPROTECTIVE AGENT; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW; CONTROLLED STUDY; CYTOPENIA; DRUG EFFECT; DRUG HALF LIFE; GAMMA RADIATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IRRADIATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MYCOPLASMA; MYCOPLASMA ARGININE; NONHUMAN; PANCYTOPENIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PROTECTION; SURVIVAL RATE; TOXICITY TESTING;

ANIMALS; BONE MARROW; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; GAMMA RAYS; HEK293 CELLS; HUMANS; LIPOPEPTIDES; MALE; MICE; MYCOPLASMA; NF-KAPPA B; PANCYTOPENIA; RADIATION INJURIES, EXPERIMENTAL; RADIATION-PROTECTIVE AGENTS; SPLEEN; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6;

MUS; MYCOPLASMA; MYCOPLASMA ARGININI;

EID: 84861368159     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2657.1     Document Type: Article

References (69)

1. Benjamin GC, McGeary M, McCutchen SR. Assessing medical preparedness to respond to a terrorist nuclear event: Workshop report. Washington DC: The National Academies Press; 2009.
2. Singh VK, Seed TM. Radiation effects. In: Roy MJ, editor. Physician's guide to terrorist attack. Totowa, NJ: Humana Press; 2003. p. 339-62.
3. Koenig KL, Goans RE, Hatchett RJ, Mettler FA Jr, Schumacher TA, Noji EK, et al. Medical treatment of radiological casualties: current concepts. Ann Emerg Med 200545:643-52. (Pubitemid 40812900)
4. Pellmar TC, Rockwell S. Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res 2005; 163:115-23. (Pubitemid 40039952)
5. Mettler FA Jr, Voelz GL. Major radiation exposure\what to expect and how to respond. N Engl J Med 2002; 346:1554-61. (Pubitemid 34755696)
6. Grdina DJ, Murley JS, Kataoka Y. Radioprotectants: current status and new directions. Oncology 2002; 63 Suppl 2:2-10. (Pubitemid 36005577)
7. Singh VK, Yadav VS. Role of cytokines and growth factors in radioprotection. Exp Mol Pathol 2005; 78:156-69. (Pubitemid 40248799)
8. Waddick KG, Song CW, Souza L, Uckun FM. Comparative analysis of the in vivo radioprotective effects of recombinant granulocyte colony-stimulating factor (G-CSF), recombinant granulocyte-macrophage CSF, and their combination. Blood 1991; 77:2364-71.
9. Whitnall MH, Elliott TB, Landauer MR, Jackson WE 3rd, Wilhelmsen CL, McKinney L, et al. In vivo protection against gamma-irradiation with 5-androstenediol. Exp Biol Med (May-wood) 2001; 226:625-7. (Pubitemid 32619600)
10. Weiss JF, Landauer MR. Radioprotection by antioxidants. Ann N Y Acad Sci 2000; 899:44-60. (Pubitemid 30352775)
11. Srinivasan V, Weiss JF. Radioprotection by vitamin E: injectable vitamin E administered alone or with WR-3689 enhances survival of irradiated mice. Int J Radiat Oncol Biol Phys 1992; 23:841-5.
12. Srinivasan V, Doctrow S, Singh VK, Whitnall MH. Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol 2008; 30:271-90. (Pubitemid 351882925)
13. Akazawa T, Masuda H, Saeki Y, Matsumoto M, Takeda K, Tsujimura K, et al. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res 2004; 64:757-64. (Pubitemid 38120920)
14. Seya T, Akazawa T, Uehori J, Matsumoto M, Azuma I, Toyoshima K. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 2003; 23:4369-76. (Pubitemid 37474889)
15. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002; 1589:1-13. (Pubitemid 34242898)
16. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 2007; 19:39-45. (Pubitemid 46084902)
17. Hertz CJ, Kiertscher SM, Godowski PJ, Bouis DA, Norgard MV, Roth MD, et al. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 2001; 166:2444-50. (Pubitemid 32173480)
18. Salazar JC, Pope CD, Sellati TJ, Feder HM Jr, Kiely TG, Dardick KR, et al. Coevolution of markers of innate and adaptive immunity in skin and peripheral blood of patients with erythema migrans. J Immunol 2003; 171:2660-70. (Pubitemid 37025580)
19. Muzio M, Bosisio D, Polentarutti N, D'Amico G, Stoppacciaro A, Mancinelli R, et al. Differential expression and regulation of tolllike receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000; 164:5998-6004. (Pubitemid 30389848)
20. Shibata K, Hasebe A, Into T, Yamada M, Watanabe T. The N-terminal lipopeptide of a 44-kDa membrane-bound lipoprotein of Mycoplasma salivarium is responsible for the expression of intercellular adhesion molecule-1 on the cell surface of normal human gingival fibroblasts. J Immunol 2000; 165:6538-44.
21. Rharbaoui F, Drabner B, Borsutzky S, Winckler U, Morr M, Ensoli B, et al. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol 2002; 32:2857-65. (Pubitemid 35238178)
22. Ruuth E, Praz F. Interactions between mycoplasmas and the immune system. Immunol Rev 1989; 112:133-60.
23. Herbelin A, Ruuth E, Delorme D, Michel-Herbelin C, Praz F. Mycoplasma arginini TUH-14 membrane lipoproteins induce production of interleukin-1, interleukin-6, and tumor necrosis factor alpha by human monocytes. Infect Immun 1994; 62:4690-4. (Pubitemid 24302016)
24. Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 1997; 185:1951-8. (Pubitemid 27247081)
25. Singh VK, Parekh VI, Brown DS, Kao TC, Mog SR. Tocopherol succinate: modulation of antioxidant enzymes and oncogene expression, and hematopoietic recovery. Int J Radiat Oncol Biol Phys 2011; 79:571-8.
26. Singh VK, Brown DS, Kao TC. Tocopherol succinate: A promising radiation countermeasure. Int Immunopharmacol 2009; 9:1423-30.
27. Xia X, Cui J, Wang HY, Zhu L, Matsueda S, Wang Q, et al. NLRX1 negatively regulates TLR-induced NF-kappaB signaling by targeting TRAF6 and IKK. Immunity 2011; 34:843-53.
28. Satyamitra M, Kulkarni S, Ghosh SP, Mullaney C, Condliffe D, Srinivasan V. Hematopoietic recovey and amelioration of radiation-induced lethality by the vitamin E isoform, delta-tocotrienol. Radiat Res 2011; 175:736-45.
29. Ghosh SP, Kulkarni S, Hieber K, Toles R, Romanyukha L, Kao TC, et al. Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int J Radiat Biol 2009; 85:598-606.
30. Ghosh SP, Perkins MW, Hieber K, Kulkarni S, Kao TC, Reddy EP, et al. Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res 2009; 171:173-9.
31. Singh VK, Brown DS, Kao TC. Alpha-tocopherol succinate protects mice from gamma-radiation by induction of granulocyte-colony stimulating factor. Int J Radiat Biol 2010; 86:12-21.
32. Whitnall MH, Inal CE, Jackson WE III, Miner VL, Villa V, Seed TM. In vivo radioprotection by 5-androstenediol: stimulation of the innate immune system. Radiat Res 2001; 156:283-93. (Pubitemid 32801097)
33. Landauer MR, Srinivasan V, Seed TM. Genistein treatment protects mice from ionizing radiation injury. J Appl Toxicol 2003; 23:379-85. (Pubitemid 37461713)
34. Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, et al. An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008; 320:226-30. (Pubitemid 351521417)
35. Hosseinimehr SJ. Trends in the development of radioprotective agents. Drug Discov Today 2007; 12:794-805. (Pubitemid 47539965)
36. Seed TM. Radiation protectants: current status and future prospects. Health Phys 2005; 89:531-45. (Pubitemid 41463887)
37. Dumont F, Le Roux A, Bischoff P. Radiation countermeasure agents: an update. Expert Opin Ther Pat 2010; 20:73-101.
38. Weiss JF, Landauer MR. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology 2003; 189:1-20. (Pubitemid 36725020)
39. Xiao M, Whitnall MH. Pharmacological countermeasures for the acute radiation syndrome. Curr Mol Pharmacol 2009; 2:122-33.
40. Satyamitra M, Uma Devi P, Murase H, Kagiya VT. In vivo postirradiation protection by a vitamin E analog, alpha-TMG. Radiat Res 2003; 160:655-61. (Pubitemid 37521708)
41. Whitnall MH, Elliott TB, Harding RA, Inal CE, Landauer MR, Wilhelmsen CL, et al. Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice. Int J Immunopharmacol 2000; 22:1-14. (Pubitemid 30102256)
42. Singh VK, Shafran RL, Inal CE, Jackson WE III, Whitnall MH. Effects of whole-body gamma irradiation and 5-androstenediol administration on serum G-CSF. Immunopharmacol Immunotox-icol 2005; 27:521-34. (Pubitemid 43220922)
43. Singh VK, Grace MB, Parekh VI, Whitnall MH, Landauer MH. Effects of genistein administration on cytokine induction in whole-body gamma irradiated mice. Int Immunopharmacol 2009; 9:1401-10.
44. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002; 62 Suppl 1:1-15.
45. Bociek RG, Armitage JO. Hematopoietic growth factors. CA Cancer J Clin 1996; 46:165-84. (Pubitemid 26169134)
46. Gerber A, Struy H, Weiss G, Lippert H, Ansorge S, Schulz HU. Effect of granulocyte colony-stimulating factor treatment on ex vivo neutrophil functions in nonneutropenic surgical intensive care patients. J Interferon Cytokine Res 2000; 20:1083-90. (Pubitemid 32015248)
47. Ishikawa K, Tanaka H, Matsuoka T, Shimazu T, Yoshioka T, Sugimoto H. Recombinant human granulocyte colony-stimulating factor attenuates inflammatory responses in septic patients with neutropenia. J Trauma 1998; 44:1047-54; discussion 1054-5.
48. Wenisch C, Werkgartner T, Sailer H, Patruta S, Krause R, Daxboeck F, et al. Effect of preoperative prophylaxis with filgrastim in cancer neck dissection. Eur J Clin Invest 2000; 30:460-6. (Pubitemid 30251404)
49. Chuang PI, Yee E, Karsan A, Winn RK, Harlan JM. A1 is a constitutive and inducible Bcl-2 homologue in mature human neutrophils. Biochem Biophys Res Commun 1998; 249:361-5. (Pubitemid 28431758)
50. Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84:1737-46. (Pubitemid 24286121)
51. Ikebuchi K, Clark SC, Ihle JN, Souza LM, Ogawa M. Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 1988; 85:3445-9.
52. Ao X, Zhao L, Davis MA, Lubman DM, Lawrence TS, Kong FM. Radiation produces differential changes in cytokine profiles in radiation lung fibrosis sensitive and resistant mice. J Hematol Oncol 2009; 2:6.
53. Chang CM, Limanni A, Baker WH, Dobson ME, Kalinich JF, Jackson WE III, et al. Bone marrow and splenic granulocyte-macrophage colony-stimulating factor and transforming growth factor-beta mRNA levels in irradiated mice. Blood 1995; 86: 2130-6.
54. Uckun FM, Souza L, Waddick KG, Wick M, Song CW. In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice. Blood 1990; 75:638-45. (Pubitemid 20069203)
55. MacVittie TJ, Farese AM. Cytokine-based treatment of radiation injury: potential benefits after low-level radiation exposure. Mil Med 2002; 167:68-70. (Pubitemid 34174189)
56. Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley AL, Dickerson WE, et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 2004; 140:1037-51.
57. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2:619-26. (Pubitemid 44650950)
58. Patchen ML, MacVittie TJ, Williams JL, Schwartz GN, Souza LM. Administration of interleukin-6 stimulates multilineage hemato-poiesis and accelerates recovery from radiation-induced hemato-poietic depression. Blood 1991; 77:472-80.
59. Patchen ML, Fischer R, MacVittie TJ. Effects of combined administration of interleukin-6 and granulocyte colony-stimulating factor on recovery from radiation-induced hemopoietic aplasia. Exp Hematol 1993; 21:338-44. (Pubitemid 24216777)
60. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989; 74:1241-4. (Pubitemid 19227430)
61. Davis TA, Clarke TK, Mog SR, Landauer MR. Subcutaneous administration of genistein prior to lethal irradiation supports multilineage, hematopoietic progenitor cell recovery and survival. Int J Radiat Biol 2007; 83:141-51.
62. Samanta AK, Oppenheim JJ, Matsushima K. Interleukin 8 (monocyte-derived neutrophil chemotactic factor) dynamically regulates its own receptor expression on human neutrophils. J Biol Chem 1990; 265:183-9.
63. Chintakuntlawar AV, Chodosh J. Chemokine CXCL1/KC and its receptor CXCR2 are responsible for neutrophil chemotaxis in adenoviral keratitis. J Interferon Cytokine Res 2009; 29:657-66.
64. Johnston CJ, Hernady E, Reed C, Thurston SW, Finkelstein JN, Williams JP. Early alterations in cytokine expression in adult compared to developing lung in mice after radiation exposure. Radiat Res 2010; 173:522-35.
65. Whitnall MH, Pellmar TC. New directions in development of pharmacological countermeasures for the acute radiation syndrome. In: Kasid UN, Notario V, Haimovitz-Friedman A, Bar-Eli M, editors. Reviews in cancer biology and therapeutics. Trivan-drum, India: Research Signpost; 2007. p. 193-209.
66. Farese AM, Casey DB, Vigneulle RM, Siegel NR, Finn RF, Klover JA, et al. A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. Stem Cells 2001; 19:514-21. (Pubitemid 33095847)
67. Arimura K, Inoue H, Kukita T, Matsushita K, Akimot M, Kawamata N, et al. Acute lung injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone. Haematologica 2005; 90:ECR10.
68. Singh VK, Brown DS, Kao TC, Seed TM. Preclinical development of a bridging therapy for radiation casualties. Exp Hematol 2010; 38:61-70.
69. Singh VK, Singh PK, Wise SY, Seed TM. Mobilized progenitor cells as a bridging therapy for radiation casualties: A brief review of tocopherol succinate-based approaches. Int Immunopharmacol 2011; 11:839-44.